

# Eric Minikel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8237246/publications.pdf>

Version: 2024-02-01

23  
papers

7,848  
citations

535685

17  
h-index

651938

25  
g-index

41  
all docs

41  
docs citations

41  
times ranked

20031  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. JCI Insight, 2022, 7, .	2.3	11
2	Implications of new genetic risk factors in prion disease. Nature Reviews Neurology, 2021, 17, 5-6.	4.9	1
3	Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2021, 597, E3-E4.	13.7	45
4	Novel quaternary structures of the human prion protein globular domain. Biochimie, 2021, 191, 118-125.	1.3	4
5	Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides. Biomolecules, 2020, 10, 1.	1.8	186
6	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research, 2020, 48, 10615-10631.	6.5	69
7	Multimodal small-molecule screening for human prion protein binders. Journal of Biological Chemistry, 2020, 295, 13516-13531.	1.6	14
8	Evaluating drug targets through human loss-of-function genetic variation. Nature, 2020, 581, 459-464.	13.7	115
9	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	13.7	6,140
10	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Medicine, 2020, 18, 140.	2.3	34
11	Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurology, The, 2020, 19, 361-368.	4.9	60
12	Autoantibodies against the prion protein in individuals with <i>PRNP</i> mutations. Neurology, 2020, 95, e2028-e2037.	1.5	7
13	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.5	73
14	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	3.3	41
15	Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry. Molecular and Cellular Proteomics, 2019, 18, 2388-2400.	2.5	22
16	Using High-Resolution Variant Frequencies Empowers Clinical Genome Interpretation and Enables Investigation of Genetic Architecture. American Journal of Human Genetics, 2019, 104, 187-190.	2.6	15
17	Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 2019, 4, .	2.3	80
18	Using high-resolution variant frequencies to empower clinical genome interpretation. Genetics in Medicine, 2017, 19, 1151-1158.	1.1	355

#	ARTICLE	IF	CITATIONS
19	Strictly co-isogenic C57BL/6J- <i>Prnp</i> <sup>0/0</sup> mice: A rigorous resource for prion science. <i>Journal of Experimental Medicine</i> , 2016, 213, 313-327.	4.2	98
20	Publicly Available Data Provide Evidence against NR1H3 R415Q Causing Multiple Sclerosis. <i>Neuron</i> , 2016, 92, 336-338.	3.8	21
21	Quantifying prion disease penetrance using large population control cohorts. <i>Science Translational Medicine</i> , 2016, 8, 322ra9.	5.8	289
22	Ascertainment Bias Causes False Signal of Anticipation in Genetic Prion Disease. <i>American Journal of Human Genetics</i> , 2014, 95, 371-382.	2.6	40
23	Measuring per Mile Risk for Pay-As-You-Drive Automobile Insurance. <i>Transportation Research Record</i> , 2012, 2297, 97-103.	1.0	36